Annual Report 2016

European Hematology Association

Koninginnegracht 12b 2514 AA The Hague

The Netherlands

RSIN/fiscal number: NL8090.86.864

1

CONTENTS ABOUT EHA .................................................................................................................................................... 2

How EHA is formed ................................................................................................................................... 2

What EHA does .......................................................................................................................................... 3

WHAT WE DID IN 2016 .................................................................................................................................. 5

CONNECTING HEMATOLOGY PROFESSIONALS IN 2016 ...................................................................... 5

Membership ........................................................................................................................................... 5

Annual congress ................................................................................................................................... 7

HARMONIZING HEMATOLOGY EDUCATION IN 2016 ........................................................................... 10

Education ............................................................................................................................................. 10

EHA-SWG Scientific Meetings ............................................................................................................ 11

EHA Master Class ............................................................................................................................... 11

Outreach ............................................................................................................................................... 12

ENCOURAGING PROFESSIONAL DEVELOPMENT ................................................................................ 13

Career development ........................................................................................................................... 13

TRTH ..................................................................................................................................................... 13

LOBBYING FOR HEMATOLOGY IN 2016 ................................................................................................ 16

Hematology Awareness Campaign ................................................................................................... 16

EU-funded projects ............................................................................................................................. 16

MAINTAINING RELATIONSHIPS AND PHILANTROPHY IN 2016 ......................................................... 17

Sponsoring ........................................................................................................................................... 17

Scientific Working Groups (SWGs) ................................................................................................... 18

EHA Friends’ Fund .............................................................................................................................. 18

FINANCIAL REPORT 2016 ........................................................................................................................... 19

Annex 1: Overview of Executive Board and Committee members ........................................................ 21

2

ABOUT EHA This annual report contains an overview of the association’s activities in 2016. These activities are all executed to support EHA’s mission:

"The European Hematology Association (EHA) promotes excellence in patient care, research and education in hematology."

EHA is a non-governmental and not-for-profit membership organization that is guided by its mission to promote excellence in patient care, research and education in hematology. In pursuing this mission, EHA acts exclusively in the interest of hematology and its practitioners and is bound by core values of independence, integrity and transparency. To ensure these interests, EHA has several instruments in place.

How EHA is formed The EHA Board is the governing body of the association and deals with issues of strategy and policy. The Board sets the goals and objectives of the association in conformity with EHA statutes.

The current Executive Board consists of:

• Tony Green, President • Christine Chomienne, Past President

• Pieter Sonneveld, President-elect • Martina Muckenthaler, Secretary • Andreas Engert, Treasurer

The EHA Board sets up committees and units to perform specific tasks and activities. Below is a list of active EHA committees:

• Communication Committee • Curriculum Committee • EHA Learning Center Editorial Board

• European Board for Accreditation in Hematology • Early Career Advisory Group • Education Committee

• European Affairs • Fellowships and Grants Committee • Fundraising and Sponsorship Committee

• Good Governance Committee • Membership Committee • Nomination Committee

• Online and Case Unit • Outreach Unit • Research Committee

• Scientific Program Committee 22nd Congress

3

• SPC Advisory Board 22nd Congress

• SWG Unit • TRTH Joint Oversight Committee

Organizational chart of EHA

The EHA Board and its committees are supported by the Executive Office which is located in The Hague, The Netherlands.

What EHA does By organizing an annual congress, providing an educational program based on the European Hematology Curriculum, publishing a journal, lobbying for hematology, promoting research, offering fellowships and mentoring programs, the association supports hematologists in and outside Europe to further improve the plight of patients suffering from blood disorders.

EHA connects hematology professionals With more than 4,000 members in 100 countries worldwide, EHA is the largest Europe-based association that connects hematology professionals and opens opportunities for both professional and personal development within the field of hematology.

EHA harmonizes hematology education EHA is one of the largest international, independent providers of peer-reviewed hematological knowledge. As a knowledge platform, the association offers a comprehensive and integral curriculum which forms the basis of the Medical Education Program (MEP). The MEP enables professionals to improve their hematology knowledge through the EHA Learning Center, master classes and scientific meetings. This allows professionals to always be aware of the latest trends, developments, publications and studies.

4

EHA makes hematology knowledge available worldwide Based on its educational program, EHA develops meetings of smaller scale and exports them outside of Europe.

EHA encourages professional development among hematologists EHA delivers on its promise to support the career of young researchers in hematology in Europe through its Career Development program. This program supports research funding, training and mentoring programs with top-tier scientists and mobility of scientists.

The EHA Career Development program includes research grants, visiting fellowships, and prestigious training and mentoring programs.

Research Grants are open for clinical and non-clinical researchers who want to achieve independence. The grants last two years and are between €50,000 and €80,000 per year.

Mobility is encouraged by offering joint programs with the Japanese Society of Hematology Exchange Fellowship, and the International Society of Thrombosis and Haemostasis, among others.

Training and mentoring programs are focused on developing the skills and knowledge of early career scientist in translational or clinical research. The EHA Clinical Research Training in Hematology is a 9-month long unique training and mentoring experience focused on clinical research in Europe, with a global scope. The ASH-EHA Translational Research Training in Hematology is a 1-year training and mentoring program by international leaders in hematology for a selected group of early career scientists from all over the world.

EHA lobbies for hematology EHA represents hematology and hematologists in the European political and policy arena.

It does so primarily by:

• raising awareness of hematology as a distinct medical discipline with specific needs • increasing the visibility of EHA as the representative of all hematologists in Europe • advocating key EHA positions vis-à-vis policymakers, politicians and interest groups

• contributing to policy debates, in order to influence future legislation/regulation • building relationships and alliances that support and strengthen our advocacy work.

By engaging with EU institutions and other relevant stakeholders – patients, other medical professions, pharmaceutical companies, issue-based expert groups – EHA promotes the interests of its members in key policy areas.

EHA strives to achieve more and better research funding opportunities, improve regulation, increase the availability and affordability of medicines, and harmonize education and training of hematologists.

5

WHAT WE DID IN 2016 CONNECTING HEMATOLOGY PROFESSIONALS IN 2016

Membership

Increase in numbers In 2016, we saw a great increase in members compared to previous years. We had over 4,360 members throughout Europe and beyond. As seen in the table below, there was an increase of 8% (338) in the total members compared to 2015. This increase is expected to continue in the years to come.

Years 2015 2016

Renews 2,960 3,167 New members 1,021 1,138 Upgraded guests 41 55 Total active members: 4,022 4,360

More members, stronger voice The overall aim is to double membership numbers within the next five years. More members strengthen the position of the association and facilitate EHA’s lobbying activities.

Because we are a worldwide organization, we have members from all around the world. The main membership base is situated in Europe. This accounts for almost 70% of all our total members.

Africa Asia Europe NorthAmerica Oceania South America

2015 113 354 2.916 351 182 1062016 85 478 3.040 429 209 119

0500

1.0001.5002.0002.5003.0003.500

6

Looking at the different countries we can see that the United Kingdom, United States, Italy, Germany, The Netherlands and Spain have the highest amount of EHA members.

The European Hematology Association provides opportunities for both professional and personal development within the field of hematology. This year, the EHA Friends’ Fund was launched and members are now able to donate money when they pay their membership fee. This is easily done by clicking on the donate button.

Membership was promoted via different communication channels like the website, leaflets, promotion emails and congress. During and after the congress, all membership types were given a 50% discount.

UnitedKingdom

UnitedStates Italy Germany Netherla

nds Spain Australia Switzerland France China

2015 408 264 321 297 267 240 162 146 148 322016 416 331 322 311 286 243 193 163 137 113

050

100150200250300350400450

7

Annual congress After eight years, the EHA Annual Congress returned to Copenhagen.The modern, glass-roofed Bella Center, one of the largest congress venues in Scandinavia with a keen eye for sustainability, suited the 21st Congress message perfectly: “keep innovating the field of hematology”.

Congress attendance breakdown Below you will find a summary of congress attendees divided geographically, by profession, field of interest, main activity and type of research.

8

Which topics were discussed There were 192 sessions at the congress. Below you will find how they were divided.

9

How the program was formed Below you will find how the program was formed.

10

HARMONIZING HEMATOLOGY EDUCATION IN 2016

Education

“They say the best way of learning is to teach. I have been involved in EHA Hematology Tutorials for over eight years. The preparation of cases for the tutorials is an excellent way of keeping up to date. I have carried out over 200 podcasts and in doing this I have met many interesting people and hopefully the interviews provide a relaxed approach to learning.” - Shaun R McCann, Ireland

Medical education program As a knowledge platform, the association offers a comprehensive and integral curriculum which forms the basis for the Medical Education Program through which professionals acquire state-of-the-art knowledge by use of various means. Through the global connection, EHA makes peer-reviewed knowledge available, which is directly applicable in practice. This allows professionals to always be aware of latest trends, developments, publications and studies.

EHA’s Medical Education Program is based on the following principles:

• CME: Continuous Medical Education • Integrated approach:

o Comprehensive state-of-the-art curriculum (eight areas of special interest)

o Cross-media (online: ELC, publications and on-site: events) o Users are informed of the latest trends, developments, publications and research,

including results

• Connects professionals with an interest in hematology on a global level • The shared knowledge is independent and peer-reviewed • Represents hematology as a mono-specialty

EHA Learning Center (official learning platform of EHA) The EHA Learning Center is expanding. Thousands of users use the Learning Center every month to read watch and browse through the extensive online learning activities and scientific materials.

With the EHA Learning Center, a broad variety of educational tools including webcasts, interviews with key opinion leaders, accredited courses and online patient cases as well as annual congress materials are made available on one platform. EHA members have free access to all peer-reviewed and evidence-based learning materials. Congress delegates have temporary and free access to annual congress materials. EHA Guests have access to materials that are freely available.

11

The focus on the development of more e-learning tools always related to one or more topics of the European Hematology Curriculum will increase in 2017.

Every month, over 2000 unique users go to the EHA Learning Center, with a clear peak around the Congress (almost 14,000 unique users).

EHA-SWG Scientific Meetings EHA facilitates 19 Scientific Working Groups (SWGs). These are active networks of scientists with an interest in particular topics. The EHA-SWG Scientific Meetings are established as scientifically-focused meetings which aim to exchange scientific knowledge and promote collaboration within the hematology community. The meetings cover both hematologic malignancies and non-malignant topics. The programs deliver experts’ perspectives on the latest findings, offer discussions with patient organizations, interactive clinical cases and round table sessions.

Furthermore, it provides an opportunity to discuss evolving therapies with leading experts in hematology as well as the opportunity to network among faculty and colleagues. The network opportunity is also always very much appreciated. The small scale meetings make it easy to talk to the faculty and other delegates.

In 2016, the focus of these meetings was on the EHA Scientific Conference on Bleeding Disorders. This meeting was organized by EHA, together with the SWG Bleeding and Thrombosis and the SWG Thrombocytopenia and Platelet Function Disorders.

The conference was attended by 130 participants from 35 countries and 6 continents, and was targeted at clinicians, basic researchers, biologists and students interested in bleeding disorders.

Furthermore, in 2016, the meeting program for 2017-2018 has been set up. An interesting program of seven EHA-SWG scientific meetings has been prepared with a wide range of topics within the hematological field.

EHA Master Class

“The Master Class has been a great experience that opened the door to another way of learning. I have met great colleagues who were really engaged with the cases as if they were from a real patient. The fact that we were having the feedback session with the case author was really motivating.” - Mariane Villegas, Sweden

The EHA Master Class is an online problem-based group learning experience for hematologists. The course, developed for junior as well as senior hematologists, is aimed to contribute to enhancing the harmonization and quality of hematology practice across Europe and beyond.

In 2016, 25 mentees successfully finished the EHA Classical Master Class of 2015-2016.

12

In that year, one bite-size course was held in February on the topics of thrombosis, thrombophilia and anticoagulation and on thalassemia. Nineteen mentees benefitted from this course.

In October, another bite-size course was held on the topics of thrombosis, thrombophilia and anticoagulation, thalassemia and clinical trials. In this course, 22 mentees have received their certificates of participation.

Outreach For many years, EHA has had an Outreach Program which is aimed at providing hematology medical education to countries outside Europe that expressed an interest in co-organizing such education and training in their county. One of the core principles in this program is that these are always organized based on the needs indicated by these countries.

EHA’s Outreach Program consists of hematology tutorials, joint symposia and Highlights of Past EHA which is based on the program of EHA’s annual congress.

Hematology Tutorials are courses aiming to provide laboratory and clinical hematologists with an integrated diagnostic and clinical work-up of hematological disorders.

In 2016, four Hematology Tutorials took place:

• EHA-ISHBT Tutorial on Myeloid Malignancies & Multiple Myeloma Mumbai, India from January 29-31, 2016 – 400 participants

• EHA-TSH Tutorial on Plasma Cell (excluding the classical multiple myeloma) Kusadasi, Turkey from March 19-20, 2016 - 32 participants

• EHA-ROHS-RSH Tutorial on Managing complications in patients with hematologic malignancies in the era of the new drugs Moscow, Russia from July 1-3, 2016 - 134 participants

• EHA-SAH Tutorial on Thrombosis, Hemostasis & Myeloid Malignancies Buenos Aires, Argentina from August 27-28, 2016 - 100 participants

In addition, the following outreach activities took place in 2016

• EHA - Pan-Arab Hematology Association Joint Program • EHA - Emirates Haematology Congress Joint Program

• EHA - Hematology Society of Taiwan - Joint Program • CSH Leukemia Congress - CSH-EHA Joint Program • EHA - Russian Onco-Hematology Society Joint Program

• EHA - Turkish Society of Hematology Joint Program • Best of EHA - Argentinian Hematology Congress • EHA - Korean Society of Hematology - Joint Program

• EHA - Indian Society of Haematology & Blood Transfusion - Joint Program

13

ENCOURAGING PROFESSIONAL DEVELOPMENT

Career development

2016 highlights • Fellowships & Grants:

o Fellowships were renamed to Research Grants

o The timeline was moved, 2016 had 2 calls open

o The administrative side was improved, a new master database was initiated, a new folder on the server

• The Early Career Advisory Group was promoted to a Committee resulting from a more proactive attitude

o Development of an Early Career session at congress highlighting CRTH and TRTH, among other things

• A new program was launched: CRTH (Clinical Research Training in Hematology) o High demand: more than 50 applications! o Learning needs were assessed beforehand, resulting in market research like

knowledge of what early career clinical researchers want o We want to use this information to develop a Master Class o Evaluations after 1st workshop were positive

• Translational Research Training in Hematology (TRTH)

TRTH The TRTH 2016 program began with a week-long course from March 11-18, 2016 in Milan, Italy during which most of the work was done. A mix of didactic sessions and breakout sessions allowed for a highly interactive learning experience.

The trainees presented their project at the start of the Spring Course, and by the end of the week, they presented an updated project that had undergone many changes and tweaks.

As preparation for the meeting at the 21st Congress of EHA, the participants were asked to read At the Helm, a book about leading your laboratory. Each small working group was asked to summarize a few chapters and present it to the others and discussed what they could apply. This session was followed by a talk by Ami Bhatt, a former TRTH participant, who described the perils and pearls of starting a lab and shared lessons on effective strategies relevant to leading a lab. The participants

14

indicated that the session was of value since it forced them to think about relevant skills and whether these skills needed training/development.

The final meeting, which took place at the 58th Annual Congress of ASH, enabled trainees to get advice from faculty regarding challenges they met while implementing strategies learnt at the course thus far. The trainees presented their learnings at the end of this session.

Achievements of past trainees Below a preliminary report can be found on the accomplishments of the trainees who participated in the first six classes of TRTH. The results reported here are based on data submitted through an online survey using Survey Monkey. A total of 115 trainees, of the 118 who participated in TRTH between 2010 and 2015, responded to the survey: response rate = 97.45%

The course has so far included slightly more men than women. Most trainees (>75%) have a medical degree.

Most trainees have changed position (72%) and 34% of past trainees now run their own lab. This entails managing staff, the budget, the research strategy and purchases.

15

Publications are an important measure of success for a trainee. TRTH alumni have published 15 papers on average, of which 5 are first/last author papers.

Identified as a critical success parameter, 43% of TRTH alumni have collaborations with other trainees and 21% with faculty members.

16

LOBBYING FOR HEMATOLOGY IN 2016

Hematology Awareness Campaign EHA launched its Hematology Awareness Campaign in 2016 which aims to:

• increase awareness of hematology as a medical discipline with its own distinct clinical and research needs, and

• enhance the position and visibility of EHA as the prime representative of hematologists in Europe.

In the first half of the year, the EHA Roadmap for European Hematology Research ( also known as Research Roadmap) and the EHA-commissioned Cost of Blood Disorders study (in The Lancet Haematology) were published. A stakeholder mapping and regulatory audit were produced, communication materials were developed and position papers were drafted.

The five position papers, approved by the Board, formulate EHA’s key lobbying priorities:

• support for hematology research in Horizon 2020 (and future EU research funding programs);

• access to treatment for patients with blood disorders; • EU collaboration to reduce the prices of innovative medicines; • the Europe-wide definition of professional qualifications in hematology; and

• improved implementation of legislation protecting the safety and quality of blood and blood components.

By the end of the summer, the campaign reached its action phase. By conducting stakeholder meetings and engaging in relevant issue-based platforms and stakeholder fora, EHA pursues the following objectives:

• Advocating key EHA positions vis-à-vis policymakers, politicians, and interest groups (patients, medical societies, pharmaceutical industry)

• Contributing to policy debates to influence future legislation/regulation

• Building relationships and alliances to be more effective at making hematology’s voice heard

EU-funded projects EHA plays a prominent role in two major EU-funded projects which were initiated in 2016:

• HARMONY is a project under the Innovative Medicines Initiative (IMI), a partnership between the European Commission and the pharmaceutical industry that aims to foster better access and care for patients with various hematologic malignancies (HM) with the use of big data.

• EuroBloodNet is the European Reference Network (ERN) for rare hematological diseases. It aims to gather expertise and data from across Europe on blood disorders, both malignant and non-malignant, which require scarce and highly-specialized knowledge and resources.

17

MAINTAINING RELATIONSHIPS AND PHILANTROPHY IN 2016

Sponsoring In 2016, EHA maintained relations with current partners and amplified collaboration, partnership and innovation by introducing new projects and activities (CRTH and SWGs). EHA’s Medical Education Program (MEP) was expanded in 2016, offering mentoring opportunities, research grants and events with updates on issues impacting the medicines and patient care. EHA is increasingly a forum for the exchange of information between the pharmaceutical industry, healthcare providers, pharmacies and other partners. In 2016, it had 28 corporate partners:

18

The interest of industry to partner with EHA is steadily growing. The EHA Annual Congress continues to be a unique networking opportunity attracting partners while programs introducing new digital technologies like the EHA Learning Center are of growing interest as well. EHA focuses on collaborative partnerships. The evolving links between the pharmaceutical industry and EHA are increasingly shifting away from a transactional relationship to a strategic partnership.

In line with EHA’s mission to promote education, research and patient care, EHA explored in the current debates on pricing models, registrars and clinical trials with industry to assess new models for innovative products in order to remain balanced and provide for access to all medicines.

In light of this, we would like to thank all partners for the excellent cooperation until now and we look forward to continuing the future innovative partnerships, patient-centered integrated care programs, corporate responsibility that makes good business sense and strong collaboration within the industry and to shape the future of healthcare provision together.

Scientific Working Groups (SWGs) The 19 Scientific Working Groups that EHA has are essential working parties for pharmaceuticals. They provide a vital link between manufacturers, pharmacies, doctors, hospitals and ultimately, the patients. They serve as a forum for collaboration and partnership between scientists in order to create win-win scenarios that ultimately benefit the well-being of patients. SWGs provide a space for learning, dialogue and exchange among everyone involved in hematology research.

The new SWG structure was created in 2016 to paint a comprehensive and up-to-date picture of research areas relevant to the field and outlines the importance from both an economic and a hematology care point of view. Focusing on the EHA Research Road Map, the new structure shows that continuous research development in Europe involves various stakeholders and need for funding.

Due to their effective function, they work on guidelines, build relationships with patient organizations and pharma and identify new innovative areas for research. They organize the EHA SWG Scientific Meetings, sessions at the EHA congress and provide scientific input for the EHA Medical Education. They help define a policy agenda for hematology and contribute to the development of EHA position papers and lobbying in Brussels.

By encouraging all SWG members to work together, EHA reflects not only on the importance of cooperation with scientists which has gained for EHA, but it also reaffirms and substantiates the association's reputation.

EHA Friends’ Fund In 2016, EHA took a major step forward with the launch of EHA Friends’ Fund. To respond to all challenges in hematology care in Europe and beyond, EHA created a fund to raise funds for research and education in hematology. The model increases the engagement with the community, demonstrates the important role of our sector and its’ benefit to patients.

19

FINANCIAL REPORT 2016

EHA is a Common Good Organization under Dutch law. Profits generated from its congress are invested in other activities to that serve the hematology community. The Board and Committee members contribute on a voluntary basis to the association’s work. Expenses for meetings are reimbursed. The EHA Executive Office has its own employment arrangements. The employees in the Executive Office function according to various job profiles, which are linked to the remuneration policy.

The remuneration (SV loon) of the management team in 2016 was € 182.366. The individual wages do not exceed the VPI (Balkenende) norm. Every year, a financial audit is executed by an independent certified auditor which resulted to a positive auditor statement in 2016. A summary of EHA’s financial position is provided below.

Balance sheet as per December 31, 2016

2016 2015 Assets Fixed assets € 170.497 € 212.291 Current Assets € 13.980.394 € 11.968.730 Total Assets € 14.150.891 € 12.181.021 Liabilities Equity € 7.627.409 € 6.664.877 Current liabilities € 6.523.482 € 5.516.144 Total liabilities € 14.150.891 € 12.181.021

State of income and expenses 2016

2016 2015 Income € 10.319.962 € 9.637.776 Expenses Annual conference € 4.872.458 € 4.957.343 Fellowships and grants € 802.786 € 1.480.468 Other and general expenses *** € 1.854.654 € 1.506.266 Activities € 1.615.583 € 1.280.858 Housing and depreciation € 198.401 € 193.376 Total expenses € 9.343.882 € 9.418.311 ---------------- ---------------- Operational result € 976.080 € 219.465 Interest & bank costs -€ 13.548 € 74.629 ---------------- ---------------- Result € 962.532 € 294.094 *** Including staff costs

20

Notes on statements:

General Accounting Principles for the preparation of the financial statements:

The financial statements are prepared according to the Netherlands Civil Code.

Validation of assets and liabilities and determination of the result takes place under the historical cost convention. Unless presented otherwise at the relevant principle for the specific balance sheet item, assets and liabilities are presented at face value. Income and expenses are accounted for on accrual basis. Profit is only included when realized on the balance sheet date. Losses originating before the end of the financial year are taken into account if they have become known before preparation of the financial statements. Revenues from services are recognized in proportion to the services rendered. The cost price of these services is allocated to the same period.

Notes on the balance sheet:

The Equity of EHA is reserved for the continuity of the organization in general. The financial aspects of these long term risks are covered by the Equity of EHA.

21

Annex 1: Overview of Executive Board and Committee members EXECUTIVE BOARD AR Green, United Kingdom (President) P Sonneveld, the Netherlands (President-elect) C Chomienne, France (Past President) M Muckenthaler, Germany (Secretary) A Engert, Germany (Treasurer) COUNCILORS S Fröhling, Germany G Gaidano, Italy J Gribben, United Kingdom S Izraeli, Israel E Macintyre, France MV Mateos, Spain HA Papadaki, Greece K Porkka, Finland F Rodeghiero, Italy V Sexl, Austria COMMUNICATION COMMITTEE A Hagenbeek, the Netherlands (Chair) J Cools, Belgium S Fröhling, Germany E Macintyre, France S McCann, Ireland I Roberts, United Kingdom M de Montalembert, France CURRICULUM COMMITTEE A Almeida, Portugal (Chair) CH Toh, United Kingdom M Cem Ar, Turkey M Guenova, Bulgaria E Hellström Lindberg, Sweden (ex-officio) M Liljeholm, Sweden JT Navarro Ferrando, Spain G Ossenkoppele, the Netherlands M Wondergem, the Netherlands EARLY CAREER COMMITTEE V Gaidzik, Germany (Chair) H Becker, Germany AK Eisfeld, USA M Gruber, USA F McClanahan, USA M Mraz, Czech Republic

C Scharenberg, Sweden EDUCATION COMMITTEE R Foà, Italy (Chair) H Akan, Turkey OW Bjerrum, Denmark C Chomienne, France J Delgado, Spain C Dufour, Italy A Ganser, Germany AR Green, United Kingdom S Modok, Hungary G Ossenkoppele, the Netherlands A Tichelli, Switzerland A Almeida, Portugal G Gaidano, Italy EHA LEARNING CENTER EDITORIAL BOARD G Ossenkoppele, the Netherlands (Chair) MC Béné, France D Bron, Belgium S Eichinger, Denmark G Gaidano, Italy N Kröger, Germany J Palmblad, Sweden K Porkka, Finland D Prati, Italy EUROPEAN AFFAIRS COMMITTEE U Jäger, Austria (Chair) C Chomienne, France A Hagenbeek, the Netherlands P Sonneveld, the Netherlands A Engert, Germany E Macintyre, France J Geissler, Germany R Hehlmann, Germany EUROPEAN BOARD FOR ACCREDITATION IN HEMATOLOGY A Tichelli, Switzerland (Chair) H Akan, Turkey M Guenova, Bulgaria H Schouten, the Netherlands M Vilarmau, Spain M Mohty, France M Lozano, Spain

1

A Falanga, Italy FELLOWSHIPS AND GRANTS COMMITTEE M Muckenthaler, Germany (Chair) JP Bourquin, Switzerland M Alberich Jorda, Czech Republic R Delwel, the Netherlands J Eikenboom, the Netherlands S Fröhling, Germany R Handgretinger, Germany T Holyoake, United Kingdom K Stamatopoulos, Greece C Thieblemont, France FUNDRAISING & SPONSOR COMMITTEE J Gribben, United Kingdom (Chair) P Sonneveld, the Netherlands R Foà, Italy K Porkka, Finland MV Mateos, Spain G Ossenkoppele, the Netherlands GOOD GOVERNANCE COMMITTEE W Fibbe, the Netherlands (Chair) T Barbui, Italy L Degos, France M Guenova, Bulgaria L Malcovati, Italy MEMBERSHIP COMMITTEE S Fröhling, Germany (Chair) J Cools, Belgium V Sexl, Austria NOMINATION COMMITTEE E Hellström Lindberg, Sweden (Chair) C Camaschella, Italy H Döhner, Germany W Fibbe, the Netherlands J San Miguel, Spain ONLINE AND CASE UNIT S Modok, Hungary (Chair) B Bain, United Kingdom J Burthem, United Kingdom S McCann, Ireland MF McMullin, Ireland C McNamara, United Kingdom M Cem Ar, Turkey

RESEARCH COMMITTEE T Green, United Kingdom (Chair) W Fibbe, The Netherlands (Co-Chair) C Bonini, Italy J Cools, Belgium R Delwel, The Netherlands S Izraeli, Israel U Jaeger, Austria MV Mateos, Spain M Muckenthaler, Germany B Porse, Denmark I Roberts, United Kingdom T Schroeder, Switzerland P Sonneveld, The Netherlands S Stilgenbauer, Germany SCIENTIFIC PROGRAM COMMITTEE 22ND CONGRESS S Izraeli, Israel (Chair) S Eichinger, Austria A Engert, Germany A Fielding, United Kingdom S Fröhling, Germany K Grønbæk, Denmark J Jansen, the Netherlands JJ Kiladjian, France N Kröger, Germany H Ludwig, Austria C Moreno, Spain M Muckenthaler, Germany G Ossenkoppele, the Netherlands JA Perez-Simon, Spain D Rees, United Kingdom A Reiter, Germany F Rodeghiero, Italy S Soverini, Italy S Stanworth, United Kingdom CH Toh, United Kingdom MM van den Heuvel-Eibrink, the Netherlands LOCAL REPRESENTATIVE 22ND CONGRESS A Alegre, Spain SCIENTIFIC PROGRAM COMMITTEE ADVISORY BOARD, 22ND CONGRESS I Aurer, Croatia H Avet-Loiseau, France C Bonini, Italy JP Bourquin, Switzerland M Delforge, Belgium

2

B Eichhorst, Germany N Gökbuget, Germany JB Hansen, Norway H Hasle, Denmark H Hasselbalch, Denmark T Holyoake, United Kingdom M Hutchings, Denmark A Iolascon, Italy P Kyrle, Austria T Lapidot, Israel JI Martin-Subero, Spain A Nagler, Israel M Olsson, Sweden RA Padua, France D Pospíšilová, Czech Republic D Prati, Italy S Saußele, Germany H Tamary, Israel A Undas, Poland SWG UNIT P Sonneveld, the Netherlands (Chair) MC Béné, France M Dreyling, Germany C Dufour, Italy

R Foà, Italy S Fröhling, Germany A Iolascon, Italy L Malcovati, Italy G Ossenkoppele, the Netherlands TRTH JOINT OVERSIGHT COMMITTEE R Delwel, the Netherlands J Licht, USA A Fielding, United Kingdom L Kean, USA M Dinauer, USA S Izraeli, Israel D Neuberg, USA (Advisor)